Sign up to save your podcasts
Or
Share Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
Link to bioRxiv paper:
http://biorxiv.org/cgi/content/short/2020.08.03.235291v1?rss=1
Authors: Iketani, S., Forouhar, F., Liu, H., Hong, S. J., Lin, F.-Y., Nair, M. S., Zask, A., Huang, Y., Xing, L., Stockwell, B. R., Chavez, A., Ho, D. D.
Abstract:
We report the identification of three structurally diverse compounds, compound 4, GC376, and MAC-5576, as inhibitors of the SARS-CoV-2 3CL protease. Structures of each of these compounds in complex with the protease revealed strategies for further development, as well as general principles for designing SARS-CoV-2 3CL protease inhibitors. These compounds may therefore serve as leads for the basis of building effective SARS-CoV-2 3CL protease inhibitors.
Copy rights belong to original authors. Visit the link for more info
View all episodes
By Multimodal LLCLink to bioRxiv paper:
http://biorxiv.org/cgi/content/short/2020.08.03.235291v1?rss=1
Authors: Iketani, S., Forouhar, F., Liu, H., Hong, S. J., Lin, F.-Y., Nair, M. S., Zask, A., Huang, Y., Xing, L., Stockwell, B. R., Chavez, A., Ho, D. D.
Abstract:
We report the identification of three structurally diverse compounds, compound 4, GC376, and MAC-5576, as inhibitors of the SARS-CoV-2 3CL protease. Structures of each of these compounds in complex with the protease revealed strategies for further development, as well as general principles for designing SARS-CoV-2 3CL protease inhibitors. These compounds may therefore serve as leads for the basis of building effective SARS-CoV-2 3CL protease inhibitors.
Copy rights belong to original authors. Visit the link for more info